Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AC4K | ISIN: US28106W1036 | Ticker-Symbol: 8EM
Tradegate
21.01.25
21:16 Uhr
1,155 Euro
-0,002
-0,13 %
1-Jahres-Chart
EDITAS MEDICINE INC Chart 1 Jahr
5-Tage-Chart
EDITAS MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1471,18213:55
1,1471,18213:37

Aktuelle News zur EDITAS MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.01.Editas Medicine-Aktie erreicht 52-Wochen-Tief bei 1,16 US-Dollar3
13.01.Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities101Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia...
► Artikel lesen
13.01.Editas Medicine, Inc. - 8-K, Current Report1
23.12.24Editas Medicine Aktie stürzt auf 52-Wochen-Tief von 1,27 US-Dollar16
23.12.24Editas Medicine stock plunges to 52-week low of $1.273
EDITAS MEDICINE Aktie jetzt für 0€ handeln
17.12.24JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution25
13.12.24Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%31
13.12.24Editas Medicine's (EDIT) "Neutral" Rating Reaffirmed at Chardan Capital9
13.12.24Editas Medicine (NASDAQ:EDIT) Downgraded to Hold Rating by Truist Financial9
13.12.24Editas axes two-thirds of its staff, including its CMO15
13.12.24Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 20266
13.12.24Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program7
13.12.24Editas lays off 65% of staff, including CMO, after fruitless search for reni-cel partner8
12.12.24Editas to lay off staff after search for sickle cell partner comes up empty2
12.12.24Editas verlagert Fokus auf In-vivo-CRISPR-Genbearbeitung11
12.12.24Editas shifts focus to in vivo CRISPR gene editing3
12.12.24Editas Medicine, Inc.: Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years133Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing...
► Artikel lesen
12.12.24Editas Medicine, Inc. - 8-K, Current Report-
12.12.24Editas Medicine stock plunges to 52-week low at $1.892
12.12.24Aktien von Editas Medicine fallen auf 52-Wochen-Tief bei 1,89 US-Dollar2
Seite:  Weiter >>
85 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1